Adrienne E Shapiro Selected Research

sotrovimab

11/2023	Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
8/2023	Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
6/2023	Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
1/2023	Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
1/2022	Early Treatment with Sotrovimab for Covid-19. Reply.
1/2022	Antibody therapy reverses biological signatures of COVID-19 progression.
1/2022	Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
11/2021	Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrienne E Shapiro Research Topics

Disease

15	COVID-19 11/2023 - 10/2020
9	Tuberculosis (Tuberculoses) 08/2023 - 11/2017
4	Pulmonary Tuberculosis 01/2024 - 01/2018
4	Disease Progression 11/2023 - 11/2021
4	Infections 01/2023 - 11/2021
2	Pneumonia (Pneumonitis) 01/2023 - 01/2022
2	Cryptococcal Meningitis 01/2023 - 01/2018
2	Reinfection 01/2021 - 10/2020
1	Alcoholism (Alcohol Abuse) 02/2024
1	Substance-Related Disorders (Drug Abuse) 02/2024
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2023
1	Viremia 01/2023
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023
1	Diarrhea 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Acquired Immunodeficiency Syndrome (AIDS) 12/2021
1	Neoplasms (Cancer) 01/2021
1	Latent Tuberculosis 08/2018

Drug/Important Bio-Agent (IBA)

8	sotrovimabIBA 11/2023 - 11/2021
6	Monoclonal AntibodiesIBA 08/2023 - 11/2021
5	Neutralizing AntibodiesIBA 08/2023 - 10/2020
3	IceIBA 11/2023 - 01/2022
2	Oxygen (Dioxygen)IBA 08/2023 - 01/2022
2	C-Reactive ProteinIBA 01/2022 - 01/2018
2	Tuberculin (PPD)IBA 12/2021 - 01/2021
2	Interferon-gamma (Interferon, gamma)IBA 12/2021 - 08/2018
2	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2021
2	Cell-Free Nucleic AcidsIBA 11/2021 - 01/2021
2	AntibodiesIBA 01/2021 - 10/2020
2	SARS-CoV-2 spike proteinIBA 01/2021 - 10/2020
2	Immunoglobulin G (IgG)IBA 01/2021 - 10/2020
2	NucleoproteinsIBA 01/2021 - 10/2020
1	TabletsIBA 02/2024
1	Opioid Analgesics (Opioids)IBA 02/2024
1	Cocaine (Cocaine HCl)IBA 02/2024
1	Nucleic AcidsIBA 01/2024
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 08/2023
1	liposomal amphotericin B FDA Link 01/2023
1	nirmatrelvir and ritonavir drug combinationIBA 01/2023
1	remdesivirIBA 01/2023
1	Flucytosine (Ancobon)FDA Link 01/2023
1	SteroidsIBA 01/2023
1	Fluconazole (Zonal)FDA LinkGeneric 01/2023
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	lipoarabinomannan (LAM)IBA 01/2022
1	N-nitrosoiminodiacetic acidIBA 12/2021
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2021
1	InterferonsIBA 01/2021
1	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021
1	SmokeIBA 11/2017
1	KeroseneIBA 11/2017

Therapy/Procedure

7	Therapeutics 01/2023 - 01/2018
2	Art Therapy 08/2023 - 01/2021
2	Transplantation 01/2022 - 01/2021
2	Critical Care (Surgical Intensive Care) 01/2022 - 10/2021
2	Donor Selection 01/2021 - 10/2020
1	Artificial Respiration (Mechanical Ventilation) 01/2022